Characteristic | N = 43 |
---|---|
Median age, years (range) | 63 (38–79) |
Male, n (%) | 27 (63) |
Asian ethnicity, n (%) | |
Chinese | 20 (47) |
Korean | 16 (37) |
Other | 7 (16) |
ECOG performance status, n (%) | |
0 | 24 (56) |
1 | 17 (40) |
2 | 2 (5) |
ISS stage, n (%) | |
I | 10 (23) |
II | 18 (42) |
III | 13 (30) |
Unknown | 2 (5) |
MM subtype, n (%) | |
IgG | 27 (63) |
IgA | 5 (12) |
Kappa light chain | 5 (12) |
Lambda light chain | 2 (5) |
Biclonal | 1 (2) |
Unknown | 3 (7) |
Lytic bone lesions, n (%) | |
Yes | 32 (74) |
No | 10 (23) |
Unknown | 1 (2) |
Median time since initial diagnosis to first dose of ixazomib, months (range) | 36.3 (8–116) |
Number of prior therapies, n (%) | |
1 | 20 (47) |
2 | 10 (23) |
3 | 12 (29) |
>3a | 1 (2) |
Prior therapy for MM, n (%) | |
Corticosteroids | 43 (100) |
Bortezomib | 32 (74) |
Thalidomide | 30 (70) |
Lenalidomide | 9 (21) |
Carfilzomib | 2 (5) |
Prior transplant, n (%) | 21 (49) |